Hackensack 385 Prospect Avenue Suite 101 Hackensack, NJ, 07601

Marlton 127 Church Road Suite 203 Marlton, NJ 08053





Long Branch 422 Morris Avenue Suite 7 Long branch, NJ 07740

Somerset 81 Veronica Avenue Suite 202 Somerset NJ 08873

Ravulizumab-cwvz(Ultomiris) Infusion orders

Date: PATIENT INFORMATION Name: DOB: SEX: M □ F \square ICD-10 description: ICD-10 code (required): □NKDA Allergies: Weight lbs/kg: **REFERRAL STATUS** ☐ Benefits Verification Only □ New Referral ☐ Referral Renewal ☐ Medication/Order Change ☐ Discontinuation Order PHYSICIAN INFORMATION Referral Coordinator Email: Referral Coordinator Name: Ordering Provider: Provider NPI: Phone: Referring Practice Name: Fax: Practice Address: City: State: Zip Code: DIAGNOSIS (and ICD 10 code) Ravulizumab-cwvz (Ultomiris) ORDERS □ Myasthenia gravis without (acute) exacerbation ICD-10 Code: G70.00 **Initial Dosing** ☐ Myasthenia gravis with (acute) exacerbation ICD-10 Code: G70.01 ☐ 2,400 mg IV (40k to less than 60kg) ☐ Other disorders of phosphorus metabolism ICD 10 Code: D59.5 2,700 mg IV(60k to less than 100 kg) Neuromyelitis Optica (NMO), Aquaporin 4 Antibody Positive □ 3,000 mg IV (100k or greater kg) ICD 10 Code: G36.0 **Maintenance Dosing** Hemolytic-uremic syndrome (aHUS) ICD 10 Code: D59.3 3,000 mg (40k to less than 60kg) IV every 8 weeks starting 2 weeks after initial load **NOTE** 3,300 mg (60k to less than 100 kg) IV every 8 weeks starting 2 **List Tried & Failed Therapies, including duration** weeks after initial load of treatment: Maintenance Dosing ONLY 1) 2) 3,000 mg (40k to less than 60kg) IV every 8 weeks 3,300 mg (60k to less than 100 kg) IV every 8 weeks Immunize patients with meningococcal vaccines at least 2 3,600 mg (100k or greater kg) IV every 8 weeks weeks prior to administering the first dose of ULTOMIRIS, ADJUST DOSE BASED ON WEIGHT (KG) AT NEXT INFUSION unless the risks of delaying ULTOMIRIS therapy outweigh the AFTER NOTIFYING DR? risk of developing a meningococcal infection. Comply with Refills*: None □X6 months □X1 year □Other: the most current National Advisory Committee on Immuniza-*(if not indicated order will expire one year from date signed) tion (NACI) recommendations for meningococcal vaccination in patients with complement **REQUIRED DOCUMENTATION:** deficiencies. ☐ This signed order form by the provider □ Patient demographics AND insurance information ☐ Clinical/ Progress notes supporting primary dx ☐ Acetylcholine Receptor Antibody Test Results (if Myasthenia Gravis)

Documentation of meningococcal vaccines WITH DATES OF ADMINISTRATION OF MEN B & MEN ACWY OR WITH DATES OF ADMINISTRATION OF MEN ABCWY OR IF NOT FULLY VACCINATED - PHROPHLATIC ANTIBX RX SENT
□ Is your patient enrolled in the Ultomiris-REMS program? □YES □No (if no, must be enrolled to start therapy) □ Is the ordering PROVIDER enrolleD in the Ultomiris-REMS program? □YES □NO (if no, must be enrolled to start therapy) =

ORDERING PROVIDER

Signature X		Date
Provider	Phone	Fax